Literature DB >> 18617914

Conditioned medium from Ad-IFN-alpha-infected bladder cancer and normal urothelial cells is cytotoxic to cancer cells but not normal cells: further evidence for a strong bystander effect.

X Zhang1, L Dong, E Chapman, W F Benedict.   

Abstract

We have reported earlier that a bystander effect is seen in cancer cells that are resistant to high concentrations of the interferon-alpha protein (Intron A) when treated with adenoviral-mediated interferon-alpha (Ad-IFN-alpha). We now provide further evidence for this bystander effect using conditioned medium (CM) collected from Ad-IFN-alpha-infected cancer and normal urothelial cells. The CMs collected from UC-9 and KU7 bladder cancer cells as well as normal urothelial cells following transfection with Ad-IFN produce cell death when added to various cancer cell types in culture but not to normal urothelial cells. The CM could be filtered, frozen and thawed, and diluted to at least one part Ad-IFN CM to five parts fresh control medium and the diluted CM still shows a similar cytotoxicity as a 100% concentration of Ad-IFN CM. This cytotoxicity was observed by both flow cytometry and MTT assays as well as by phase microscopy, and a significant sub-G1 population was seen whether the CM was collected 48, 72 or 96 h after initial Ad-IFN treatment. In addition, the CM could be partially inactivated by exposure to 65 degrees C for 30 min and totally inactivated by placement at 92 degrees C for 3 min, whereas Intron A was not inactivated under the same conditions. Importantly, although significant caspase 8 and caspase 9 cleavage occurred in Ad-IFN-treated cells as a direct effect of Ad-IFN transfection, the Ad-IFN CM produced no activation of caspase 8 and caspase 9, indicating that a different mechanism of cell death was produced by the bystander factor(s) than the direct effect of Ad-IFN. This bystander effect in turn may play an important role in the efficacy of the current Ad-IFN clinical trial for superficial bladder cancer now underway.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18617914      PMCID: PMC4070368          DOI: 10.1038/cgt.2008.53

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  5 in total

1.  Efficacy of a single intravesical treatment with Ad-IFN/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation.

Authors:  Z Tao; R J Connor; F Ashoori; C P N Dinney; M Munsell; J A Philopena; W F Benedict
Journal:  Cancer Gene Ther       Date:  2006-02       Impact factor: 5.987

2.  Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells.

Authors:  Angela Papageorgiou; Laura Lashinger; Randall Millikan; H Barton Grossman; William Benedict; Colin P N Dinney; David J McConkey
Journal:  Cancer Res       Date:  2004-12-15       Impact factor: 12.701

3.  Adenoviral-mediated interferon alpha overcomes resistance to the interferon protein in various cancer types and has marked bystander effects.

Authors:  X Zhang; Z Yang; L Dong; A Papageorgiou; D J McConkey; W F Benedict
Journal:  Cancer Gene Ther       Date:  2006-11-10       Impact factor: 5.987

4.  Expression of hTERT immortalises normal human urothelial cells without inactivation of the p16/Rb pathway.

Authors:  E J Chapman; C D Hurst; E Pitt; P Chambers; J S Aveyard; M A Knowles
Journal:  Oncogene       Date:  2006-04-17       Impact factor: 9.867

5.  Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein.

Authors:  William F Benedict; Ziming Tao; Chang-Soo Kim; Xinqiao Zhang; Jain-Hua Zhou; Liana Adam; David J McConkey; Angela Papageorgiou; Mark Munsell; Jennifer Philopena; Heidrun Engler; William Demers; Daniel C Maneval; Colin P N Dinney; Robert J Connor
Journal:  Mol Ther       Date:  2004-09       Impact factor: 11.454

  5 in total
  9 in total

1.  Direct gene transfer of adenoviral-mediated interferon α into human bladder cancer cells but not the bystander factors produced induces endoplasmic reticulum stress-related cytotoxicity.

Authors:  X-Q Zhang; Z Yang; W F Benedict
Journal:  Cancer Gene Ther       Date:  2010-12-24       Impact factor: 5.987

Review 2.  The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside.

Authors:  Jonathan J Duplisea; Sharada Mokkapati; Devin Plote; Kimberly S Schluns; David J McConkey; Seppo Yla-Herttuala; Nigel R Parker; Colin P Dinney
Journal:  World J Urol       Date:  2018-11-11       Impact factor: 4.226

3.  A trial of intrapleural adenoviral-mediated Interferon-α2b gene transfer for malignant pleural mesothelioma.

Authors:  Daniel H Sterman; Andrew Haas; Edmund Moon; Adriana Recio; Daniel Schwed; Anil Vachani; Sharyn I Katz; Colin T Gillespie; Guanjun Cheng; Jing Sun; Emmanouil Papasavvas; Luis J Montaner; Daniel F Heitjan; Leslie Litzky; Joseph Friedberg; Melissa Culligan; Carl H June; Richard G Carroll; Steven M Albelda
Journal:  Am J Respir Crit Care Med       Date:  2011-06-03       Impact factor: 21.405

4.  Direct cytotoxicity produced by adenoviral-mediated interferon α gene transfer in interferon-resistant cancer cells involves ER stress and caspase 4 activation.

Authors:  Z Yang; X-Q Zhang; C N P Dinney; W F Benedict
Journal:  Cancer Gene Ther       Date:  2011-06-17       Impact factor: 5.987

5.  Autophagy is induced by adenoviral-mediated interferon alpha treatment in interferon resistant bladder cancer and normal urothelial cells as a cell death protective mechanism but not by the bystander factors produced.

Authors:  X-Q Zhang; K Dunner; W F Benedict
Journal:  Cancer Gene Ther       Date:  2010-05-21       Impact factor: 5.987

6.  Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer.

Authors:  Colin P N Dinney; Mark B Fisher; Neema Navai; Michael A O'Donnell; David Cutler; Alice Abraham; Sophia Young; Beth Hutchins; Maria Caceres; Narendra Kishnani; George Sode; Constance Cullen; Guangcheng Zhang; H Barton Grossman; Ashish M Kamat; Marshall Gonzales; Michael Kincaid; Nancy Ainslie; Daniel C Maneval; Matthew F Wszolek; William F Benedict
Journal:  J Urol       Date:  2013-03-15       Impact factor: 7.450

7.  Use of monitoring levels of soluble forms of cytokeratin 18 in the urine of patients with superficial bladder cancer following intravesical Ad-IFNα/Syn3 treatment in a phase l study.

Authors:  W F Benedict; M Fisher; X-Q Zhang; Z Yang; M F Munsell; C N P Dinney
Journal:  Cancer Gene Ther       Date:  2014-02-07       Impact factor: 5.987

8.  Molecular characterization of type I IFN-induced cytotoxicity in bladder cancer cells reveals biomarkers of resistance.

Authors:  Jennifer L Green; Robin E Osterhout; Amy L Klova; Carsten Merkwirth; Scott R P McDonnell; Reza Beheshti Zavareh; Bryan C Fuchs; Adeela Kamal; Jørn S Jakobsen
Journal:  Mol Ther Oncolytics       Date:  2021-11-12       Impact factor: 7.200

9.  Measuring soluble forms of extracellular cytokeratin 18 identifies both apoptotic and necrotic mechanisms of cell death produced by adenoviral-mediated interferon alpha: possible use as a surrogate marker.

Authors:  M B Fisher; X-Q Zhang; D J McConkey; W F Benedict
Journal:  Cancer Gene Ther       Date:  2009-02-06       Impact factor: 5.987

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.